Literature DB >> 21281602

Activation of H-Ras and Rac1 correlates with epidermal growth factor-induced invasion in Hs578T and MDA-MB-231 breast carcinoma cells.

Min-Soo Koh1, Aree Moon.   

Abstract

There is considerable experimental evidence that hyperactive Ras proteins promote breast cancer growth and development including invasiveness, despite the low frequency of mutated forms of Ras in breast cancer. We have previously shown that H-Ras, but not N-Ras, induces an invasive phenotype mediated by small GTPase Rac1 in MCF10A human breast epithelial cells. Epidermal growth factor (EGF) plays an important role in aberrant growth and metastasis formation of many tumor types including breast cancer. The present study aims to investigate the correlation between EGF-induced invasiveness and Ras activation in four widely used breast cancer cell lines. Upon EGF stimulation, invasive abilities and H-Ras activation were significantly increased in Hs578T and MDA-MB-231 cell lines, but not in MDA-MB-453 and T47D cell lines. Using small interfering RNA (siRNA) to target H-Ras, we showed a crucial role of H-Ras in the invasive phenotype induced by EGF in Hs578T and MDA-MB-231 cells. Moreover, siRNA-knockdown of Rac1 significantly inhibited the EGF-induced invasiveness in these cells. Taken together, this study characterized human breast cancer cell lines with regard to the relationship between H-Ras activation and the invasive phenotype induced by EGF. Our data demonstrate that the activation of H-Ras and the downstream molecule Rac1 correlates with EGF-induced breast cancer cell invasion, providing important information on the regulation of malignant progression in mammary carcinoma cells.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281602     DOI: 10.1016/j.bbrc.2011.01.092

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Ras Signaling in Breast Cancer.

Authors:  Aree Moon
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation.

Authors:  Kyung Hun Lee; Minsoo Koh; Aree Moon
Journal:  Oncol Lett       Date:  2016-07-11       Impact factor: 2.967

3.  Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.

Authors:  Alfeu Zanotto-Filho; Subapriya Rajamanickam; Eva Loranc; V Pragathi Masamsetti; Aparna Gorthi; July Carolina Romero; Sonal Tonapi; Rosangela Mayer Gonçalves; Robert L Reddick; Raymond Benavides; John Kuhn; Yidong Chen; Alexander J R Bishop
Journal:  Cancer Lett       Date:  2018-03-30       Impact factor: 8.679

4.  Targeting of Rac GTPases blocks the spread of intact human breast cancer.

Authors:  Elad Katz; Andrew H Sims; Duncan Sproul; Helen Caldwell; Michael J Dixon; Richard R Meehan; David J Harrison
Journal:  Oncotarget       Date:  2012-06

5.  Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC).

Authors:  S Skvortsov; J Dudás; P Eichberger; M Witsch-Baumgartner; J Loeffler-Ragg; C Pritz; V H Schartinger; H Maier; J Hall; P Debbage; H Riechelmann; P Lukas; I Skvortsova
Journal:  Br J Cancer       Date:  2014-05-01       Impact factor: 7.640

6.  Triptolide inhibits vascular endothelial growth factor-mediated angiogenesis in human breast cancer cells.

Authors:  Huantao Liu; Lubing Tang; Xiaoyan Li; Huiying Li
Journal:  Exp Ther Med       Date:  2018-05-21       Impact factor: 2.447

7.  Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study.

Authors:  Ramya Ambur Sankaranarayanan; Jennifer Peil; Andreas T J Vogg; Carsten Bolm; Steven Terhorst; Arno Classen; Matthias Bauwens; Jochen Maurer; Felix Mottaghy; Agnieszka Morgenroth
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

8.  Association of RAC1 Gene Polymorphisms with Primary End-Stage Renal Disease in Chinese Renal Recipients.

Authors:  Yani Liu; Jiali Zhou; Xiaomei Luo; Chunxiao Yang; Yu Zhang; Shaojun Shi
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

9.  Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.

Authors:  Jangsoon Lee; Rachael Galloway; Geoff Grandjean; Justin Jacob; Juliane Humphries; Chandra Bartholomeusz; Samantha Goodstal; Bora Lim; Geoffrey Bartholomeusz; Naoto T Ueno; Arvind Rao
Journal:  J Cancer       Date:  2015-10-28       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.